The PMOS Body Map: What Insulin Resistance Does Beyond Your Ovaries

If your diagnosis came from a gynaecologist, the conversation probably stopped at your cycle. Maybe a scan, maybe a prescription for the pill, maybe a line about fertility "when you're ready." What rarely gets said in that room is that the same hormonal wiring behind an irregular period also runs through your liver, your sleep, your blood vessels and your mood.

That's the quiet argument inside the new name. PCOS (now PMOS) — Polyendocrine Metabolic Ovarian Syndrome, renamed by The Lancet in May 2026 — puts "metabolic" in the middle of the word for a reason. The ovaries are where the condition was first seen. They were never the whole of it.

This piece is the map. Not to alarm you — most of what follows is risk, not destiny — but because you can't ask about an organ no one told you was involved.

Insulin resistance is the hub, not a symptom

Start here, because almost everything else branches off it. The majority of women with PMOS have some degree of insulin resistance — and crucially, that includes lean women, where a normal BMI hides it. Insulin resistance means the body has to pump out more insulin to do the same job. That extra insulin is the thread connecting the rooms below.

It tells the ovaries to make more testosterone. It tells the liver to store more fat. It nudges blood pressure and cholesterol the wrong way. So when you read the rest of this as a list of separate "risks," remember they mostly share one root. Treat the root and several of these move together.

The liver: the comorbidity nobody mentions

Fatty liver — now called MASLD, metabolic-dysfunction-associated steatotic liver disease — is the most under-discussed PMOS link, partly because it's silent. A 2023 systematic review and meta-analysis put the pooled prevalence of fatty liver in PCOS at around 43%, and the association held even in non-obese women (odds roughly doubled, independent of weight). A 2025 cohort that scanned livers directly found steatosis in about 36% of PCOS participants versus 24% of controls.

You won't feel this one. It shows up on a liver ultrasound or in liver enzymes on a blood panel — tests that aren't part of a standard "PCOS workup." It's worth knowing the word exists, because the next time bloods are ordered, ALT and a note on the liver are reasonable things to ask for.

Sleep: the link that explains the exhaustion

If you're tired in a way that sleep doesn't fix, this is the room to read twice. Obstructive sleep apnoea — breathing that repeatedly pauses in the night — is far more common in PMOS than most women are told. A 2025 systematic review found a pooled prevalence near 37% in women with PCOS versus about 6% without, with the odds several times higher even after accounting for weight.

It's a loop, not a coincidence. Poor sleep worsens insulin resistance; insulin resistance worsens sleep. Snoring, gasping, waking unrefreshed, daytime fog — these are screenable, and treatable, and they're not "just stress."

Heart and blood sugar, across the whole lifespan

The cardiometabolic thread doesn't end at menopause — it may sharpen there. A 2026 Maturitas paper, written under the new PMOS name, argues for tracking this risk across a woman's entire life rather than treating PMOS as a reproductive-years problem that resolves when periods do. The same insulin resistance behind the rooms above also nudges blood pressure and cholesterol the wrong way — and it shows up most measurably as blood sugar: the risk of type 2 diabetes runs roughly two to four times the general population, with the glucose drift often starting years before a diagnosis is ever made.

This is also where the honest hedge belongs. Most of these numbers are associations from cross-sectional and cohort studies, not proof that PMOS causes each outcome in any one person. The 2026 research is still mapping the wiring — a recent review even frames it as a "gut-heart-ovary axis," which tells you how much is still being worked out. Elevated risk is a reason to screen, not a verdict.

What this changes for you

Not your life overnight. Your questions.

The single most useful shift is to stop thinking "I have a period problem" and start thinking "I have a metabolic condition that shows up in several places." That reframe is what gets the right tests ordered: fasting insulin and HOMA-IR rather than glucose alone, a lipid panel, liver enzymes, and an honest conversation about sleep. In Asian populations we'd flag metabolic risk earlier — at a BMI of 23, not the Western 25 — because the risk arrives at a lower weight.

And the hopeful part of one shared root: the levers that lower insulin resistance — the right supplement for your subtype, and for some women the GLP-1 evidence — tend to move more than one room at a time.

You don't need to memorise this map. You just need to know it's bigger than the ovaries, so the next appointment asks bigger questions.

If you want to see which parts of this apply to you, our free 5-minute assessment walks through your symptoms and subtype — and shows you a result without asking for anything in return.

Citations

• Teede HJ, et al. The Lancet, 12 May 2026 — the PMOS rename consensus.
• Systematic review and meta-analysis of NAFLD/MASLD in PCOS, 2023 — pooled prevalence ~43%; association independent of obesity.
• Systematic review of obstructive sleep apnoea in PCOS, 2025 — pooled prevalence ~37% vs ~6% in non-PCOS.
• Cohort study of type 2 diabetes, MASLD and cardiovascular risk in PCOS, 2025 — direct liver imaging; elevated incident T2D.
• Maturitas, 2026 — "Menopause and PMOS: redefining cardiometabolic risk across the lifespan."